文献速递消化系统肿瘤

红细胞包裹门冬酰胺酶联合化疗二线治疗晚期胰腺癌的IIb期随机试验

Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
PubMed 文献 · Eur J Cancer · 2019-11-21

这项开放标签IIb期试验将141例晚期胰腺腺癌患者按2:1随机分配至eryaspase联合吉西他滨或mFOLFOX6组(95例)或单纯化疗组(46例)。低ASNS表达患者中,联合组中位OS为6.2个月对4.9个月(HR 0.63,P=0.056),中位PFS为2.0个月对1.8个月(HR 0.67,P=0.127);全人群中联合组OS和PFS均显著改善。联合治疗耐受良好。

要点

  • 全人群中eryaspase联合化疗较单纯化疗显著改善OS(6.0对4.4个月,HR 0.60,P=0.008)和PFS(2.0对1.6个月,HR 0.56,P=0.005)。
  • 低ASNS表达患者中OS和PFS改善未达统计学显著(OS P=0.056,PFS P=0.127)。
  • 联合治疗耐受良好,最常见的3/4级不良事件为GGT升高(17.2%)、中性粒细胞减少(12.9%)和体力状况恶化(12.9%)。

核心结论

  • Eryaspase联合化疗在晚期胰腺腺癌二线治疗中与OS和PFS改善相关,且不依赖于ASNS表达水平。

研究设计与样本

  • 开放标签、随机IIb期试验(NCT02195180),纳入141例晚期胰腺腺癌患者,按2:1随机分配至eryaspase联合吉西他滨或mFOLFOX6组(n=95)或吉西他滨或mFOLFOX6单药组(n=46)。
  • 共同主要终点为低ASNS表达患者的OS和PFS,次要终点为全人群的OS和PFS。

主要发现

  • 低ASNS表达患者中,联合组与对照组的中位OS分别为6.2个月(95%CI 5.1-8.8)和4.9个月(95%CI 3.1-7.1),HR 0.63(95%CI 0.39-1.01),P=0.056。
  • 低ASNS表达患者中,联合组与对照组的中位PFS分别为2.0个月(95%CI 1.8-3.4)和1.8个月(95%CI 1.4-3.8),HR 0.67(95%CI 0.40-1.12),P=0.127。
  • 全人群中,联合组与对照组的中位OS分别为6.0个月和4.4个月,HR 0.60,P=0.008。
  • 全人群中,联合组与对照组的中位PFS分别为2.0个月和1.6个月,HR 0.56(95%CI 0.37-0.84),P=0.005。
  • 联合组(n=93)最常见的3/4级不良事件为γ-谷氨酰转移酶升高(16例,17.2%)、中性粒细胞减少(12例,12.9%)和体力状况恶化(12例,12.9%)。

临床怎么用

  • 对于晚期胰腺腺癌二线治疗,eryaspase联合吉西他滨或mFOLFOX6可能改善生存,且无需依据ASNS表达筛选患者。
  • 联合方案耐受良好,需关注γ-谷氨酰转移酶升高、中性粒细胞减少和体力状况恶化等3/4级不良事件。

局限性

  • 本研究为IIb期开放标签试验,样本量有限(共141例),结果需III期试验验证。
  • 低ASNS表达患者中OS和PFS的改善未达到预设的统计学显著性(P值分别为0.056和0.127)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This Phase IIb (NCT02195180) open-label study evaluated erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy in second-line advanced pancreatic adenocarcinoma. METHODS: Eligible patients were randomized 2:1 to either eryaspase in combination with gemcitabine or mFOLFOX6 (eryaspase arm), or to gemcitabine or mFOLFOX6 alone (control arm). Co-primary endpoints were overall survival (OS) and progression-free survival (PFS) in patients with low asparagine synthetase (ASNS) expression. Secondary endpoints included OS and PFS in the entire population. RESULTS: 141 patients were randomized (eryaspase arm, n = 95; control arm, n = 46). Median OS and PFS in patients with low ASNS expression were 6.2 months (95% CI, 5.1-8.8) in the eryaspase arm versus 4.9 months (3.1-7.1) in the control arm (HR, 0.63; 95% CI, 0.39-1.01; P = 0.056) and 2.0 months (95% CI, 1.8-3.4) in the eryaspase arm versus 1.8 months (1.4-3.8) in the control arm (HR, 0.67; 95% CI, 0.40-1.12; P = 0.127), respectively. In the entire population, median OS and PFS for the eryaspase arm versus control were 6.0 months versus 4.4 months (HR, 0.60; P = 0.008) and 2.0 months versus 1.6 months (HR, 0.56; 95% CI, 0.37-0.84; P = 0.005), respectively. The combination of eryaspase and chemotherapy was well tolerated. The most frequent Grade 3/4 adverse events in the eryaspase arm (n = 93) were gamma-glutamyltransferase increase (16 [17.2%]), neutropenia (12 [12.9%]), and physical health deterioration (12 [12.9%]). CONCLUSION: Eryaspase in combination with chemotherapy is associated with improvements in OS and PFS, irrespective of ASNS expression in second-line advanced pancreatic adenocarcinoma. A Phase III trial is underway.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hammel P, Fabienne P, Mineur L, et al. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. Eur J Cancer. 2019. PMID: 31760314. doi:10.1016/j.ejca.2019.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。